Cintas (NASDAQ: CTAS) and Interpace Diagnostics Group (NASDAQ:IDXG) are both industrials companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitabiliy and analyst recommendations.
This is a breakdown of current ratings for Cintas and Interpace Diagnostics Group, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Interpace Diagnostics Group||0||0||0||0||N/A|
Cintas currently has a consensus price target of $132.73, suggesting a potential downside of 0.43%. Given Cintas’ higher probable upside, equities analysts plainly believe Cintas is more favorable than Interpace Diagnostics Group.
Volatility and Risk
Cintas has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Interpace Diagnostics Group has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.
Insider and Institutional Ownership
68.6% of Cintas shares are owned by institutional investors. Comparatively, 1.4% of Interpace Diagnostics Group shares are owned by institutional investors. 19.1% of Cintas shares are owned by insiders. Comparatively, 2.5% of Interpace Diagnostics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Cintas and Interpace Diagnostics Group’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Cintas||$5.32 billion||2.64||$1.05 billion||$4.38||30.43|
|Interpace Diagnostics Group||$13.52 million||0.57||-$10.02 million||N/A||N/A|
Cintas has higher revenue and earnings than Interpace Diagnostics Group.
This table compares Cintas and Interpace Diagnostics Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Interpace Diagnostics Group||-8.45%||-28.77%||-5.44%|
Cintas pays an annual dividend of $1.33 per share and has a dividend yield of 1.0%. Interpace Diagnostics Group does not pay a dividend. Cintas pays out 30.4% of its earnings in the form of a dividend. Interpace Diagnostics Group has raised its dividend for 34 consecutive years.
Cintas beats Interpace Diagnostics Group on 11 of the 14 factors compared between the two stocks.
Cintas Company Profile
Cintas Corporation is a provider of corporate identity uniforms through rental and sales programs, as well as a provider of related business services, including entrance mats, restroom cleaning services and supplies, carpet and tile cleaning services, first aid and safety services and fire protection products and services. Its segments include uniform rental and facility services, and first aid and safety services. Its uniform rental and facility service segment offers services, which include rental and servicing of uniforms and other garments, including flame resistant clothing, mats, mops and shop towels, and other ancillary items. Its first aid and safety service segment offers services, which include first aid and safety products and services. Rental processing plants, rental branches, first aid and safety facilities, fire protection facilities, direct sales offices, distribution centers and manufacturing facilities are all utilized by the businesses included in All Other.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.
Receive News & Ratings for Cintas Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cintas Co. and related companies with MarketBeat.com's FREE daily email newsletter.